Literature DB >> 23532511

Cross-validation for nonlinear mixed effects models.

Emily Colby1, Eric Bair.   

Abstract

Cross-validation is frequently used for model selection in a variety of applications. However, it is difficult to apply cross-validation to mixed effects models (including nonlinear mixed effects models or NLME models) due to the fact that cross-validation requires "out-of-sample" predictions of the outcome variable, which cannot be easily calculated when random effects are present. We describe two novel variants of cross-validation that can be applied to NLME models. One variant, where out-of-sample predictions are based on post hoc estimates of the random effects, can be used to select the overall structural model. Another variant, where cross-validation seeks to minimize the estimated random effects rather than the estimated residuals, can be used to select covariates to include in the model. We show that these methods produce accurate results in a variety of simulated data sets and apply them to two publicly available population pharmacokinetic data sets.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23532511      PMCID: PMC3668859          DOI: 10.1007/s10928-013-9313-5

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  17 in total

1.  Nonlinear mixed effects models for repeated measures data.

Authors:  M L Lindstrom; D M Bates
Journal:  Biometrics       Date:  1990-09       Impact factor: 2.571

2.  Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.

Authors:  Julie Bertrand; Emmanuelle Comets; Céline M Laffont; Marylore Chenel; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-27       Impact factor: 2.745

3.  Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group.

Authors:  J M Bailey; C T Mora; S L Shafer
Journal:  Anesthesiology       Date:  1996-06       Impact factor: 7.892

4.  Population pharmacokinetics of theophylline during paediatric extracorporeal membrane oxygenation.

Authors:  Hussain Mulla; Fazal Nabi; Sanjiv Nichani; Graham Lawson; R K Firmin; David R Upton
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

5.  The effect of obesity on apparent volume of distribution of theophylline.

Authors:  T M Rohrbaugh; M Danish; M C Ragni; S J Yaffe
Journal:  Pediatr Pharmacol (New York)       Date:  1982

6.  Population pharmacokinetics of ciprofloxacin in pediatric patients.

Authors:  Prabhu Rajagopalan; Marc R Gastonguay
Journal:  J Clin Pharmacol       Date:  2003-07       Impact factor: 3.126

7.  Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting.

Authors:  K Zomorodi; A Donner; J Somma; J Barr; R Sladen; J Ramsay; E Geller; S L Shafer
Journal:  Anesthesiology       Date:  1998-12       Impact factor: 7.892

8.  Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements.

Authors:  A C Hooker; A J Ten Tije; M A Carducci; J Weber; E Garrett-Mayer; H Gelderblom; W P McGuire; J Verweij; M O Karlsson; S D Baker
Journal:  Clin Pharmacol Ther       Date:  2008-01-09       Impact factor: 6.875

9.  Theophylline disposition in obesity.

Authors:  P Gal; W J Jusko; A M Yurchak; B A Franklin
Journal:  Clin Pharmacol Ther       Date:  1978-04       Impact factor: 6.875

10.  Pharmacokinetics of computer-controlled alfentanil administration in children undergoing cardiac surgery.

Authors:  P Fiset; L Mathers; R Engstrom; D Fitzgerald; S C Brand; F Hsu; S L Shafer
Journal:  Anesthesiology       Date:  1995-11       Impact factor: 7.892

View more
  5 in total

1.  Polymorphic Expression of UGT1A9 is Associated with Variable Acetaminophen Glucuronidation in Neonates: A Population Pharmacokinetic and Pharmacogenetic Study.

Authors:  Matthew W Linakis; Sarah F Cook; Shaun S Kumar; Xiaoxi Liu; Diana G Wilkins; Roger Gaedigk; Andrea Gaedigk; Catherine M T Sherwin; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

2.  Development and Evaluation of a Prediction Model for Ascertaining Rheumatic Heart Disease Status in Administrative Data.

Authors:  D Bond-Smith; R Seth; N de Klerk; L Nedkoff; M Anderson; J Hung; J Cannon; K Griffiths; J M Katzenellenbogen
Journal:  Clin Epidemiol       Date:  2020-07-09       Impact factor: 4.790

3.  Supplementing Claims Data with Electronic Medical Records to Improve Estimation and Classification of Rheumatoid Arthritis Disease Activity: A Machine Learning Approach.

Authors:  Candace H Feldman; Kazuki Yoshida; Chang Xu; Michelle L Frits; Nancy A Shadick; Michael E Weinblatt; Sean E Connolly; Evo Alemao; Daniel H Solomon
Journal:  ACR Open Rheumatol       Date:  2019-09-04

4.  Exposure-Response Modeling to Support Dosing Selection for Phase IIb Development of Kukoamine B in Sepsis Patients.

Authors:  Huanhuan Wang; Xiaoyun Hu; Teng Wang; Cheng Cui; Ji Jiang; Kai Dong; Shuai Chen; Chunyan Jin; Qian Zhao; Bin Du; Pei Hu
Journal:  Front Pharmacol       Date:  2021-04-19       Impact factor: 5.810

5.  Ground reaction force estimates from ActiGraph GT3X+ hip accelerations.

Authors:  Jennifer M Neugebauer; Kelsey H Collins; David A Hawkins
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.